Core Insights - Jazz Pharmaceuticals announced improved outcomes for adults with narcolepsy or idiopathic hypersomnia treated with Xywav, as demonstrated in the Phase 4 DUET study [1][2] - The company is committed to addressing neurological disorders with limited treatment options, emphasizing the importance of ongoing data generation for Xywav and Epidiolex [3] Xywav Treatment Insights - The Phase 4 DUET trial showed statistically significant improvements in Epworth Sleepiness Scale (ESS) scores, reduced sleep stage shifts, increased deep sleep, and fewer awakenings in adults with narcolepsy treated with Xywav [2] - In adults with idiopathic hypersomnia, Xywav treatment also resulted in improvements in ESS and Idiopathic Hypersomnia Severity Scale scores [2] - Patient-reported data indicated that Xywav treatment was associated with improvements in daytime symptoms and cognitive complaints among adults with narcolepsy or idiopathic hypersomnia [2] Epidiolex Treatment Insights - A novel analysis of real-world Epidiolex treatment patterns revealed a nearly 70% (69.9%) probability of persistence at one year among new patients, highlighting the importance of dose optimization [5] - The analysis indicated that 52% of patients were taking dosages greater than 15 mg/kg/day at 12 months, with those on average dosages greater than 20 mg/kg/day having the lowest likelihood of discontinuation [5] Upcoming Presentations - Jazz Pharmaceuticals will present seven abstracts at the 2025 AAN Annual Meeting, focusing on the effectiveness and safety of Xywav and real-world data on Epidiolex [1][4]

Market Overview - The U.S. stock market is expected to remain volatile due to uncertainty surrounding trade policies, economic concerns, and shifts in investor sentiment, particularly influenced by President Trump's tariffs on major trading partners [1] - Retaliatory measures from trading partners have heightened market anxiety, despite temporary rebounds from hopes for tariff concessions [1] - Key economic indicators such as jobless claims, payroll reports, and corporate earnings are likely to further influence market movements [1] Investment Strategy - Creating a curated portfolio of low-beta stocks is recommended as a strategy to safeguard against market fluctuations [2] - Low-beta stocks such as The Progressive Corporation (PGR), Pearson plc (PSO), TXO Partners LP (TXO), and Jazz Pharmaceuticals plc (JAZZ) are highlighted as potential investment opportunities [2] Company Highlights The Progressive Corporation (PGR) - In 2024, PGR reported a 21% year-over-year increase in net premiums written, totaling $74.4 billion, with active policies growing by over 5 million [7] - The company achieved an 88.8 combined ratio, outperforming its 96 target, driven by strong claims management and operational efficiencies [7] - PGR's competitive advantages in pricing and customer service position it well for continued growth in the insurance sector [7] Pearson plc (PSO) - Pearson experienced a 3% sales growth in 2024, with profits rising by 10% and an EBIT margin of 16.9% [9] - Strategic partnerships with AWS and Microsoft are enhancing Pearson's AI capabilities and expanding enterprise learning opportunities [9] - The company's leadership in assessments and innovative digital offerings support its long-term growth outlook [9] Jazz Pharmaceuticals plc (JAZZ) - Jazz Pharmaceuticals reported annual revenues exceeding $4 billion in 2024, with fourth-quarter revenues reaching a record $1.09 billion [10] - The company's diversified portfolio in sleep, epilepsy, and oncology continues to drive growth, with key products showing strong performance [10] - Robust cash flow and a strong pipeline position JAZZ for continued growth and value creation [10] TXO Partners LP (TXO) - TXO Partners has a strong presence in the oil-rich Permian Basin, benefiting from exploration and production activities [11] - The Mancos Shale project, covering 58,500 contiguous acres, holds nearly 3 trillion cubic feet of natural gas potential, which could significantly increase reserves [11] - Phase I of the project targets a 3,520-acre block estimated to hold 200-300 billion cubic feet of natural gas, potentially doubling existing reserves [11]